• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Letrozole and abemaciclib in estrogen receptor–positive recurrent endometrial cancer

byDaniel GoldshteinandSze Wah Samuel Chan
December 28, 2022
in Chronic Disease, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Almost half of patients (47%) had either an objective response or had progression free survival for at least 6 months after starting therapy.

2. Most common adverse events included diarrhea, fatigue, elevated creatinine, neutropenia, and anemia.

Evidence Rating Level: 2 (Good)

Study Rundown: Estrogen is a primary oncogenic driver of most endometrial cancers (EC). Hormone therapy alone, however, shows modest benefit for most patients. Recent studies have found phosphatidylinositol 3-kinase (PI3K) and receptor tyrosine kinase (RTK)/RAS/b-catenin (CTNNB1) pathways, which are present in most EC, are involved in endocrine therapy resistance through another pathway; upregulation of cyclin D1, cyclin-dependent kinases 4 and 6 (CDK4/6), retinoblastoma, transcription factor E2F, ultimately upregulating transcription of genes and tumor progression. This study looked at a combination therapy of aromatase inhibitor letrozole with CDK4/6 inhibitor abemaciclib in estrogen receptor (ER)-positive recurrent EC. Primary endpoints included objective response (OR) or progression-free survival (PFS) for at least 6 months after starting therapy. Secondary endpoints included duration of PFS, overall survival (OS), duration of response (DOR), and adverse events. Almost a third of patients were found to have a partial OR, more than a third had stable disease, and less than a third had disease progression. Altogether, almost half of patients were found to meet either of the primary end points. Most common adverse events included diarrhea, fatigue, elevated creatinine, neutropenia, and anemia. Biomarkers were also analyzed from most patients and the following was found; no significant association between progesterone receptor status and response to treatment, TP53 mutations had reduced clinical benefit, mismatch repair deficiency was found to have clinical benefit. Limitations to this study included a small sample size, lack of a control group, and lack of diversity in patients. Strengths of this study included investigation of biomarkers. Overall, letrozole and abemaciclib shows some effect in ER–positive recurrent endometrial cancer and should be further investigated.

Click to read the study in JCO

Relevant Reading: Integrated genomic characterization of endometrial carcinoma

In-Depth [prospective cohort]: This is a single-arm, two-stage, phase II study that investigated the efficacy of abemaciclib (150 mg by mouth twice daily) and letrozole (2.5 mg by mouth once daily) in patients with pathologically confirmed ER-positive EC which was recurrent or metastatic and found to be resistant to standard therapy. A total of 30 patients were enrolled with a median follow-up time of 12.5 months. Almost half of patients were found to meet either of the primary end points (46.7%, 95%CI, 28.3 to 65.7). They found a partial OR in 30% (95%CI, 14.7 to 49.4) of patients, another 43% of patients experienced stability in their disease and 23% had progressive disease. OR were found in patients with endometrioid EC and those patients had a median DOR of 7.4 months. Generally median PFS was 9.1 months (95%CI, 3.5 to 16.5) and median OS was 21.6 months. Most common adverse events included diarrhea (70%), fatigue (67%), and elevated creatinine (33%), with adverse events grade 3 or higher being neutropenia (20%) and anemia (17%). With regards to biomarkers, which were analyzed from 90% of patients, they found no significant association between progesterone receptor status and response to treatment. Three patients had mismatch repair deficiency and all three were found to have clinical benefit, meanwhile it was found that only 18% of TP53-mutated vs 82% of TP53 wild type patients found clinical benefit. Overall, the combination of letrozole and abemaciclib have some positive effect in ER–positive recurrent endometrial cancer and there is a need for further investigation.

RELATED REPORTS

#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation

#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer

Endovaginal ultrasound highly sensitive screen for endometrial cancer [Classics Series]

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: abemaciclibendometrial cancerletrozole
Previous Post

Low income associated with increased BMI and chronic stress

Next Post

Fulvestrant for treatment of estrogen receptor-positive, HER2-negative advanced breast cancer may improve progression free survival using ESR1 mutation as guidance

RelatedReports

#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation
StudyGraphics

#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation

January 31, 2023
#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer
StudyGraphics

#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer

January 24, 2023
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Chronic Disease

Endovaginal ultrasound highly sensitive screen for endometrial cancer [Classics Series]

August 9, 2022
#VisualAbstract: Maintenance endocrine therapy plus bevacizumab after induction with paclitaxel is effective for ER+ breast cancers
StudyGraphics

#VisualAbstract: Maintenance endocrine therapy plus bevacizumab after induction with paclitaxel is effective for ER+ breast cancers

August 2, 2022
Next Post
JAK2 and TET2 mutations temporally linked with myeloproliferative disorder outcomes

Fulvestrant for treatment of estrogen receptor-positive, HER2-negative advanced breast cancer may improve progression free survival using ESR1 mutation as guidance

dermatomyositis

Intravenous immune globulin improved disease severity in dermatomyositis

Intensive rehabilitation not superior to traditional therapy for arm function after stroke

Cerebral embolic protection during transcatheter aortic-valve replacement does not reduce the incidence of stroke

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Low-dose pirfenidone may be noninferior to standard dosing in patients with idiopathic pulmonary fibrosis
  • Protein-truncating variants in apolipoprotein B and PCSK9 genes associated with lower exposure to atherogenic LDL cholesterol and risk of coronary heart disease
  • College campus monkeypox outbreaks can be controlled with timely detection and isolation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options